- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Pfizer Slapped With Rs 8.79 Cr GST Demand Over Alleged ITC Irregularities, Plans Appeal
PfizerNew Delhi: Pfizer has received a tax demand order amounting to Rs 8.79 crore, including penalty, from the Office of the Additional Commissioner of GST and Central Excise, Kolkata, following a GST audit conducted for the state of West Bengal.
In a regulatory filing, the company said the order was issued on December 27, 2025, under Section 74 of the Goods and Services Tax Act, 2017, covering the financial years 2018-19 to 2022-23.
According to the disclosure made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the tax authority has raised a GST demand of Rs 4,39,55,698 along with an equivalent penalty of Rs 4,39,55,698, aggregating to a total demand of Rs 8,79,11,396, excluding applicable interest. The demand has been raised on allegations of incorrect availment of Input Tax Credit (ITC) by Pfizer Limited during the audited period.
The pharmaceutical major, however, has disputed the findings of the GST department. Pfizer stated that based on the Company’s assessment, the Company believes that the said demand is not maintainable.
The Company is in the process of preferring an appeal against the said Order. The Order has no material impact on the financials, operations, or other activities of the Company.
In compliance with SEBI’s disclosure norms and the recent circular issued on November 11, 2024, Pfizer has also provided additional details, confirming that the order was passed by the Additional Commissioner of GST and CX, Kolkata jurisdiction, and was issued under Section 74 of the GST Act, which deals with cases involving alleged suppression or willful misstatement.
On the impact of the order, Pfizer Limited clarified,
"Based on the assessment, we believe that the said demand is not maintainable, and the Company is in the process of preferring an appeal against the said Order.The Order has no material impact on the financials, operations or other activities of the Company."
Mpharm (Pharmacology)
Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.

